DKSH Acquires Rocephin Antibiotic Brand Rights from Roche
DKSH has acquired the rights to the antibiotic brand Rocephin from Roche.
Stocks · News reference
Roche has launched the Ventana BAP1 (SP527) test, an automated tissue diagnostic tool designed to assist in the identification of malignant mesothelioma.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
DKSH has acquired the rights to the antibiotic brand Rocephin from Roche.
Goldman Sachs has revised its price target for Roper Technologies, increasing it to $468 from the previous $410.
Argus has increased its price target for Roper Technologies, moving it from $450 to $480.